O'Neill F J, Frisque R J, Xu X, Hu Y X, Carney H
Department of Veterans Affairs Research Service, Salt Lake City, Utah 84148.
Oncogene. 1995 Mar 16;10(6):1131-9.
Human fibroblasts were morphologically transformed with wild type and mutant SV40 T-antigens (T-Ags) and with SV40/JCV and SV40/BKV chimeric T-Ags. The transformants were then assayed for the attainment of immortal cell growth. Several observations relating T-Ag and T-Ag domains to immortalization were made. Approximately 10% of SV40-transformants became immortal. Transformants generated by transfection or infection of cells with C-terminal T-Ag deletion mutants of SV40 did not immortalize. SV40/JCV and SV40/BKV chimeric T-Ags, containing C-terminal sequences from JCV or BKV, immortalized cells more efficiently than did the intact SV40 T-Ag, suggesting that the C-termini of the JCV and BKV T-Ags contain an enhanced immortalization function. However, chimeras in which the N-terminal or proximal-central portions of T-Ag were composed of JCV sequences failed to immortalize but did induce transformation. Constructs in which the JCV T-Ag Rb binding domain was replaced with SV40 sequences transformed human cells, but again the cells failed to immortalize. Transformants and immortalized cell lines produced by some SV40/JCV chimeras, contained p53 which was unbound by T-Ag. This occurred under conditions where p53 from SV40 and SV40/BKV transformants was bound to T-Ag. This may reflect the reduced stability of the SV40/JCV T-Ags.
用人成纤维细胞与野生型及突变型猿猴病毒40(SV40)大T抗原(T-Ag)以及SV40/人多瘤病毒(JCV)和SV40/人乳头瘤病毒(BKV)嵌合T-Ag进行形态学转化。然后检测转化体是否获得永生细胞生长特性。得出了一些将T-Ag和T-Ag结构域与永生化相关联的观察结果。约10%的SV40转化体变为永生细胞。用SV40的C末端T-Ag缺失突变体转染或感染细胞所产生的转化体未实现永生化。含有JCV或BKV C末端序列的SV40/JCV和SV40/BKV嵌合T-Ag使细胞永生化的效率高于完整的SV40 T-Ag,这表明JCV和BKV T-Ag的C末端含有增强的永生化功能。然而,T-Ag的N末端或近中心部分由JCV序列组成的嵌合体未能使细胞永生化,但确实诱导了转化。将JCV T-Ag的Rb结合结构域替换为SV40序列的构建体转化了人细胞,但细胞再次未能永生化。一些SV40/JCV嵌合体产生的转化体和永生细胞系含有未与T-Ag结合的p53。这发生在SV40和SV40/BKV转化体的p53与T-Ag结合的条件下。这可能反映了SV40/JCV T-Ag稳定性的降低。